Boston Scientific (NYSE:BSX) said the FDA approved the latest set of its pacemakers, including a device designed to treat patients who can’t regulate their heartbeats while exercising.
The Natick, Mass.-based med-tech maker said the watchdog agency granted pre-market approval for its Ingenio and Advantio pacemakers and for its Invive cardiac resynchronization therapy pacer.
Sign up to get our free newsletters delivered straight to your inbox
The first U.S. implant of an Ingenio device happened May 3 at the Cleveland Clinic, according to a press release. That device and the Advantio are designed to treat "chronotropic incompetence" –
the inability to properly regulate heart rate during physical activity. Boston Scientific said the devices use a sensor to measure "minute ventilation," saying it’s "the only sensor clinically proven to restore chronotropic competence." The Ingenio model also measures respiration rate, the company said.
Last month BSX won CE Mark approval for the Ingenio line of devices in the European Union.
Roche’s Ventana Medical Systems wins 510(k) for p53 (DO-7) apps
Angioslide wins 510(k) for Proteus below-the-knee embolism capture device
